UCB S.A. UNSP.ADR 1/2 (UNC0) - Total Assets
Based on the latest financial reports, UCB S.A. UNSP.ADR 1/2 (UNC0) holds total assets worth €18.16 Billion EUR (≈ $21.23 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See UNC0 book value for net asset value and shareholders' equity analysis.
UCB S.A. UNSP.ADR 1/2 - Total Assets Trend (2021–2025)
This chart illustrates how UCB S.A. UNSP.ADR 1/2's total assets have evolved over time, based on quarterly financial data. Check UNC0 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
UCB S.A. UNSP.ADR 1/2 - Asset Composition Analysis
Current Asset Composition (December 2025)
UCB S.A. UNSP.ADR 1/2's total assets of €18.16 Billion consist of 33.3% current assets and 66.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.4% |
| Accounts Receivable | €1.33 Billion | 7.3% |
| Inventory | €1.50 Billion | 8.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.45 Billion | 19.0% |
| Goodwill | €5.09 Billion | 28.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how UCB S.A. UNSP.ADR 1/2's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see UCB S.A. UNSP.ADR 1/2 (UNC0) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: UCB S.A. UNSP.ADR 1/2's current assets represent 33.3% of total assets in 2025, an increase from 26.1% in 2021.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, up from 8.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, a decrease from 58.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 28.0% of total assets.
UCB S.A. UNSP.ADR 1/2 Competitors by Total Assets
Key competitors of UCB S.A. UNSP.ADR 1/2 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $146.48 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩130.74 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥773.72 Million |
UCB S.A. UNSP.ADR 1/2 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 1.36 | 1.19 |
| Quick Ratio | 1.04 | 0.99 | 0.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.65 Billion | €1.26 Billion | €522.00 Million |
UCB S.A. UNSP.ADR 1/2 - Advanced Valuation Insights
This section examines the relationship between UCB S.A. UNSP.ADR 1/2's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.03 |
| Latest Market Cap to Assets Ratio | 2.47 |
| Asset Growth Rate (YoY) | 4.7% |
| Total Assets | €18.16 Billion |
| Market Capitalization | $44.84 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values UCB S.A. UNSP.ADR 1/2's assets at a significant premium (2.47x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: UCB S.A. UNSP.ADR 1/2's assets grew by 4.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for UCB S.A. UNSP.ADR 1/2 (2021–2025)
The table below shows the annual total assets of UCB S.A. UNSP.ADR 1/2 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €18.16 Billion ≈ $21.23 Billion |
+4.68% |
| 2024-12-31 | €17.35 Billion ≈ $20.28 Billion |
+11.64% |
| 2023-12-31 | €15.54 Billion ≈ $18.17 Billion |
-2.07% |
| 2022-12-31 | €15.87 Billion ≈ $18.55 Billion |
+11.67% |
| 2021-12-31 | €14.21 Billion ≈ $16.61 Billion |
-- |
About UCB S.A. UNSP.ADR 1/2
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthr… Read more